1
|
Zhang Y, Ding Y, Li M, Yuan J, Yu Y, Bi X, Hong H, Ye J, Liu P. MicroRNA-34c-5p provokes isoprenaline-induced cardiac hypertrophy by modulating autophagy via targeting ATG4B. Acta Pharm Sin B 2022; 12:2374-2390. [PMID: 35646533 PMCID: PMC9136534 DOI: 10.1016/j.apsb.2021.09.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 08/30/2021] [Accepted: 08/31/2021] [Indexed: 02/06/2023] Open
Abstract
Pathological cardiac hypertrophy serves as a significant foundation for cardiac dysfunction and heart failure. Recently, growing evidence has revealed that microRNAs (miRNAs) play multiple roles in biological processes and participate in cardiovascular diseases. In the present research, we investigate the impact of miRNA-34c-5p on cardiac hypertrophy and the mechanism involved. The expression of miR-34c-5p was proved to be elevated in heart tissues from isoprenaline (ISO)-infused mice. ISO also promoted miR-34c-5p level in primary cultures of neonatal rat cardiomyocytes (NRCMs). Transfection with miR-34c-5p mimic enhanced cell surface area and expression levels of foetal-type genes atrial natriuretic factor (Anf) and β-myosin heavy chain (β-Mhc) in NRCMs. In contrast, treatment with miR-34c-5p inhibitor attenuated ISO-induced hypertrophic responses. Enforced expression of miR-34c-5p by tail intravenous injection of its agomir led to cardiac dysfunction and hypertrophy in mice, whereas inhibiting miR-34c-5p by specific antagomir could protect the animals against ISO-triggered hypertrophic abnormalities. Mechanistically, miR-34c-5p suppressed autophagic flux in cardiomyocytes, which contributed to the development of hypertrophy. Furthermore, the autophagy-related gene 4B (ATG4B) was identified as a direct target of miR-34c-5p, and miR-34c-5p was certified to interact with 3' untranslated region of Atg4b mRNA by dual-luciferase reporter assay. miR-34c-5p reduced the expression of ATG4B, thereby resulting in decreased autophagy activity and induction of hypertrophy. Inhibition of miR-34c-5p abolished the detrimental effects of ISO by restoring ATG4B and increasing autophagy. In conclusion, our findings illuminate that miR-34c-5p participates in ISO-induced cardiac hypertrophy, at least partly through suppressing ATG4B and autophagy. It suggests that regulation of miR-34c-5p may offer a new way for handling hypertrophy-related cardiac dysfunction.
Collapse
Key Words
- 3-MA, 3-methyladenine
- 3′ UTR, 3′ untranslated region
- ANF, atrial natriuretic factor
- ATG4B
- ATG4B, autophagy related gene 4B
- Autophagic flux
- Autophagy
- BNP, brain natriuretic polypeptide
- Baf A1, bafilomycin A1
- CQ, Chloroquine
- EF, ejection fraction
- FS, fractional shortening
- GFP, green fluorescent protein
- HE, hematoxylin–eosin
- ISO, isoprenaline
- IVS,d: interventricular septal wall dimension at end-diastole, IVS,s: interventricular septal well dimension at end-systole
- Isoprenaline
- LC3
- LC3, microtubule-associated protein 1 light chain 3
- LV Vol,d, left ventricular end-diastolic volume
- LV Vol,s, left ventricular end-systolic volume
- LVID,d, left ventricular end-diastolic internal diameter
- LVID,s, left ventricular end-systolic internal diameter
- LVPW,d, left ventricular end-diastolic posterior wall thickness
- LVPW,s, left ventricular end-systolic posterior wall thickness
- Mice
- NS, normal saline
- Neonatal rat cardiomyocytes
- PSR, Picric–Sirius red
- Pathological cardiac hypertrophy
- mTOR, mammalian target of rapamycin
- miR-34c-5p
- miRNA, microRNA
- qRT-PCR, quantitative real-time polymerase chain reaction
- β-AR, β-adrenergic receptor
- β-MHC, beta-myosin heavy chain
Collapse
|
2
|
Wang P, Wang M, Hu Y, Chen J, Cao Y, Liu C, Wu Z, Shen J, Lu J, Liu P. Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression. Acta Pharm Sin B 2021; 11:680-693. [PMID: 33777675 PMCID: PMC7982427 DOI: 10.1016/j.apsb.2020.10.017] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2020] [Revised: 08/22/2020] [Accepted: 08/24/2020] [Indexed: 12/16/2022] Open
Abstract
As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of YAP1 in Dox-induced cardiomyopathy has not been reported. In this study, the expression of YAP1 was reduced in clinical human failing hearts with dilated cardiomyopathy and Dox-induced in vivo and in vitro cardiotoxic model. Ectopic expression of Yap1 significantly blocked Dox-induced cardiomyocytes apoptosis in TEAD1 dependent manner. Isorhapontigenin (Isor) is a new derivative of stilbene and responsible for a wide range of biological processes. Here, we found that Isor effectively relieved Dox-induced cardiomyocytes apoptosis in a dose-dependent manner in vitro. Administration with Isor (30 mg/kg/day, intraperitoneally, 3 weeks) significantly protected against Dox-induced cardiotoxicity in mice. Interestingly, Isor increased Dox-caused repression in YAP1 and the expression of its target genes in vivo and in vitro. Knockout or inhibition of Yap1 blocked the protective effects of Isor on Dox-induced cardiotoxicity. In conclusion, YAP1 may be a novel target for Dox-induced cardiotoxicity and Isor might be a new compound to fight against Dox-induced cardiotoxicity by increasing YAP1 expression.
Collapse
Key Words
- AMPK, AMP-activated protein kinase
- AP-1, anti-microbial protein
- AREG, amphiregulin
- AUC/Dose, dose-normalized plasma exposures
- Amphiregulin
- Ang II, angiotensin II
- CO, cardiac output
- CTGF, connective tissue growth factor
- Cardiomyocytes apoptosis
- Cardiotoxicity
- Cmax/Dose, dose-normalized maximal plasma concentrations
- Connective tissue growth factor
- DAB, 3,3′-diaminobenzidine
- DMEM, Dulbecco's modified Eagle's medium
- Dob, dobutamine
- Dox, doxorubicin
- Doxorubicin
- EMT, epithelial mesenchymal transformation
- FOXO1, forkhead box class O1
- FS, fractional shortening
- HE, hematoxylin–eosin
- ISO, isoproterenol
- Isor, isorhapontigenin
- Isorhapontigenin
- LVAW;d, left ventricular end-diastolic anterior wall thickness
- LVAW;s, left ventricular end-systolic anterior wall thickness
- LVEF, left ventricular ejection fraction
- LVID;d, left ventricular end-diastolic internal diameter
- LVID;s, left ventricular end-systolic internal diameter
- LVPW;d, left ventricular end-diastolic posterior wall thickness
- LVPW;s, left ventricular end-systolic posterior wall thickness
- MAPK, mitogen-activated protein kinase
- MI, myocardial infarction
- NF-κB, nuclear factor kappa-B
- NRCMs, neonatal rat cardiomyocytes
- P2Y12 receptor, ADP receptor
- PGC-1α, peroxisome proliferator-activated receptor γ coactivator-1α
- PMSF, phenylmethanesulfonyl fluoride
- PVDF, polyvinylidene fluoride
- ROS, reactive oxygen species
- SD, Sprague–Dawley
- SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis
- SESN2, sestrin2
- TCF4, T-cell factor 4
- TEAD, TEA domain transcription factor proteins
- TEAD1
- TUNEL, TdT-mediated dUTP nick end labeling
- WGA, wheat germ agglutinin
- YAP1
- YAP1, Yes-associated protein 1
- qRT-PCR, quantitative real-time polymerase chain reaction
- sgRNAs, sequence guiding RNAs
- Δψm, mitochondrial membrane potential
Collapse
Affiliation(s)
- Panxia Wang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Minghui Wang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Yuehuai Hu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Jianxing Chen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Yanjun Cao
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Cui Liu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
| | - Zhongkai Wu
- Department of Cardiac Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
| | - Juan Shen
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou 510006, China
- Corresponding authors.
| | - Jing Lu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
- Corresponding authors.
| | - Peiqing Liu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou 510006, China
- Guangdong Provincial Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou 510006, China
- Corresponding authors.
| |
Collapse
|
3
|
Merdji H, Mayeur S, Schenck M, Oulehri W, Clere-Jehl R, Cunat S, Herbrecht JE, Janssen-Langenstein R, Nicolae A, Helms J, Meziani F, Chenard MP. Histopathological features in fatal COVID-19 acute respiratory distress syndrome. Med Intensiva 2021; 45:261-270. [PMID: 34054173 PMCID: PMC7914021 DOI: 10.1016/j.medin.2021.02.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2021] [Accepted: 02/05/2021] [Indexed: 12/15/2022]
Abstract
Background COVID-19 acute respiratory distress syndrome (ARDS) shares the common histological hallmarks with other forms of ARDS. However, the chronology of the histological lesions has not been well established. Objective To describe the chronological histopathological alterations in the lungs of patients with COVID-19 related ARDS. Design A prospective cohort study was carried out. Setting Intensive Care Unit of a tertiary hospital. Patients The first 22 consecutive COVID-19 deaths. Measurements Lung biopsies and histopathological analyses were performed in deceased patients with COVID-19 related ARDS. Clinical data and patient course were evaluated. Results The median patient age was 66 [63–74] years; 73% were males. The median duration of mechanical ventilation was 17 [8–24] days. COVID-19 induced pulmonary injury was characterized by an exudative phase in the first week of the disease, followed by a proliferative/organizing phase in the second and third weeks, and finally an end-stage fibrosis phase after the third week. Viral RNA and proteins were detected in pneumocytes and macrophages in a very early stage of the disease, and were no longer detected after the second week. Limitation Limited sample size. Conclusions The chronological evolution of COVID-19 lung histopathological lesions seems to be similar to that seen in other forms of ARDS. In particular, lung lesions consistent with potentially corticosteroid-sensitive lesions are seen.
Collapse
Key Words
- ACE2, angiotensin-converting enzyme 2
- AFOP, acute fibrinous and organizing pneumonia
- ARDS, acute respiratory distress syndrome
- COVID-19
- COVID-19 related acute respiratory distress syndrome
- COVID-19, coronavirus infectious disease
- DAD, diffuse alveolar damage
- HE, hematoxylin–eosin
- Histopathology
- ISH, in situ hybridization
- NMBD, neuromuscular blocking drugs
- RT-PCR, Reverse Transcriptase-Polymerase chain reaction
- SAPSII, simplified acute physiology score
- SARS-CoV-2
- SOFA, Sequential Organ Failure Assessment
- VILI, ventilator induced lung injury
Collapse
Affiliation(s)
- H Merdji
- Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
| | - S Mayeur
- Département de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - M Schenck
- Service de Médecine Intensive - Réanimation, Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - W Oulehri
- Service d'Anesthésie - Réanimation Chirurgicale, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France
| | - R Clere-Jehl
- Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France
| | - S Cunat
- Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - J-E Herbrecht
- Service de Médecine Intensive - Réanimation, Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - R Janssen-Langenstein
- Service de Médecine Intensive - Réanimation, Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - A Nicolae
- Département de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - J Helms
- Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France
| | - F Meziani
- Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
| | - M-P Chenard
- Département de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Centre de Ressources biologiques, Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | |
Collapse
|
4
|
Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B 2019; 9:745-757. [PMID: 31384535 PMCID: PMC6664044 DOI: 10.1016/j.apsb.2019.02.006] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 12/11/2018] [Accepted: 01/11/2019] [Indexed: 02/07/2023] Open
Abstract
Non-alcoholic steatohepatitis (NASH) is a chronic metabolic syndrome and the CFLAR-JNK pathway can reverse the process of NASH. Although silibinin is used for the treatment of NASH in clinical, its effect on CFLAR-JNK pathway in NASH remains unclear. This study aimed to investigate the effect of silibinin on CFLAR-JNK pathway in NASH models both in vivo and in vitro. The in vivo study was performed using male C57BL/6 mice fed with methionine- choline-deficient diet and simultaneously treated with silibinin for 6 weeks. The in vitro study was performed by using mouse NCTC-1469 cells which were respectively pretreated with oleic acid plus palmitic acid, and adenovirus-down Cflar for 24 h, then treated with silibinin for 24 h. After the drug treatment, the key indicators involved in CFLAR-JNK pathway including hepatic injury, lipid metabolism and oxidative stress were determined. Silibinin significantly activated CFLAR and inhibited the phosphorylation of JNK, up-regulated the mRNA expression of Pparα, Fabp5, Cpt1α, Acox, Scd-1, Gpat and Mttp, reduced the activities of serum ALT and AST and the contents of hepatic TG, TC and MDA, increased the expression of NRF2 and the activities of CAT, GSH-Px and HO-1, and decreased the activities and expression of CYP2E1 and CYP4A in vivo. These effects were confirmed by the in vitro experiments. Silibinin prevented NASH by regulating CFLAR-JNK pathway, and thereby on one hand promoting the β-oxidation and efflux of fatty acids in liver to relieve lipid accumulation, and on the other hand inducing antioxidase activity (CAT, GSH-Px and HO-1) and inhibiting pro-oxidase activity (CYP2E1 and CYP4A) to relieve oxidative stress.
Collapse
Key Words
- 2-NBDG, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-deoxyglucose
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- Acox, acyl-coenzyme A oxidase X
- Akt, serine–threonine protein kinase
- CAT, catalase
- CFLAR
- CFLAR, caspase 8 and Fas-associated protein with death domain-like apoptosis regulator
- CYP2E1, cytochrome P450 2E1
- CYP4A, cytochrome P450 4A
- Cpt1α, carnitine palmitoyl transferase 1α
- Fabp5, fatty acid-binding proteins 5
- GSH-Px, glutathione peroxidase
- Gpat, glycerol-3-phosphate acyltransferase
- HE, hematoxylin–eosin
- HO-1, heme oxygenase 1
- IR, insulin resistance
- IRS1, insulin receptor substrate 1
- JNK, c-Jun N-terminal kinase
- Lipid accumulation
- MAPK, mitogen-activated protein kinase
- MCD, methionine- and choline-deficient
- MCS, methionine- and choline-sufficient
- MDA, malondialdehyde
- MT, Masson–Trichrome
- Mttp, microsomal triglyceride transfer protein
- NAFLD, non-alcoholic fatty liver disease
- NASH
- NASH, nonalcoholic steatohepatitis
- NF-κB, nuclear factor κB
- NRF2, nuclear factor erythroid 2-related factor 2
- OA, oleic acid
- ORO, oil red O
- Oxidation stress
- PA, palmitic acid
- PI3K, phosphatidylinositol 3-hydroxy kinase
- Pnpla3, phospholipase domain containing 3
- Pparα, peroxisome proliferator activated receptor α
- SD, Sprague–Dawley
- Scd-1, stearoyl-coenzyme A desaturase-1
- Silibinin
- Srebp-1c, sterol regulatory element binding protein-1C
- TC, total cholesterol
- TG, triglyceride
- pIRS1, phosphorylation of insulin receptor substrate 1
- pJNK, phosphorylation of c-Jun N-terminal kinase
Collapse
Affiliation(s)
| | | | | | | | - Yong Chen
- Hubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei University, Wuhan 430062, China
| |
Collapse
|
5
|
Ramos CAF, Sá RDCDS, Alves MF, Benedito RB, de Sousa DP, Diniz MDFFM, Araújo MST, de Almeida RN. Histopathological and biochemical assessment of d-limonene-induced liver injury in rats. Toxicol Rep 2015; 2:482-488. [PMID: 28962384 PMCID: PMC5598502 DOI: 10.1016/j.toxrep.2015.01.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2014] [Revised: 12/31/2014] [Accepted: 01/01/2015] [Indexed: 11/01/2022] Open
Abstract
The aim of the present work was to develop a biochemical, histologic and immunohistochemical study about the potential hepatotoxic effect of d-limonene - a component of volatile oils extracted from citrus plants. Blood alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) from d-limonene-treated animals were determined and compared to morphologic hepatic lesions in order to investigate the possible physiopathologic mechanisms involved in the liver toxicity, in experimental animals treated with d-limonene. Wistar rats were randomly divided into seven groups: two control groups (untreated or receiving only vehicle, tween-80); one positive control (vehicle); two experimental groups treated with d-limonene at doses of 25 mg/kg/day and 75 mg/kg/day for 45 days, and two other groups treated with the same doses for 30 days and kept under observation during 30 more days. Biochemical data showed significant reduction in ALT levels in the animals treated with 75 mg/kg of d-limonene. Histological analysis revealed some hepatocyte morphological lesions, including hydropic degeneration, microvesicular steatosis and necrosis, Kupffer cell hyperplasia and incipient fibrosis. By immunohistochemistry, influx of T (CD3+) and cytotoxic (CD8+) lymphocytes was observed in the rats treated with d-limonene at both dose levels. In conclusion, it is possible that d-limonene has been directly responsible for hepatic parenchymal and matrix damage following subchronic treatment with d-limonene.
Collapse
Affiliation(s)
- Carlos Alberto F Ramos
- Post-graduation Program in Bioactive Synthetic and Natural Products, Health Sciences Center, Federal University of Paraíba, Brazil
| | - Rita de Cássia da S Sá
- Post-graduation Program in Bioactive Synthetic and Natural Products, Health Sciences Center, Federal University of Paraíba, Brazil
| | - Mateus F Alves
- Post-graduation Program in Bioactive Synthetic and Natural Products, Health Sciences Center, Federal University of Paraíba, Brazil
| | - Rubens B Benedito
- Post-graduation Program in Bioactive Synthetic and Natural Products, Health Sciences Center, Federal University of Paraíba, Brazil
| | - Damião P de Sousa
- Pharmaceutics Science Department, Health Sciences Center, Federal University of Paraíba, Brazil
| | - Margareth de Fátima F M Diniz
- Post-graduation Program in Bioactive Synthetic and Natural Products, Health Sciences Center, Federal University of Paraíba, Brazil.,Pharmaceutics Science Department, Health Sciences Center, Federal University of Paraíba, Brazil
| | | | - Reinaldo N de Almeida
- Post-graduation Program in Bioactive Synthetic and Natural Products, Health Sciences Center, Federal University of Paraíba, Brazil.,Physiology and Pathology Department, Health Sciences Center, Federal University of Paraíba, Brazil
| |
Collapse
|